ImmunoAIzer contains two components: (1) a semi-supervised cellular biomarker distribution prediction network (CBDPN) which can make predictions of the spatial distribution of CD3, CD20, PanCK, and DAPI on H&E images; (2) a tumor gene mutation detection network (TGMDN), which can detect APC, TP53, and KRAS gene mutations from H&E images. Here, KRAS is linked to neoplasm.